MXPA04003508A - Anticuerpos humanos que se unen a mn. - Google Patents

Anticuerpos humanos que se unen a mn.

Info

Publication number
MXPA04003508A
MXPA04003508A MXPA04003508A MXPA04003508A MXPA04003508A MX PA04003508 A MXPA04003508 A MX PA04003508A MX PA04003508 A MXPA04003508 A MX PA04003508A MX PA04003508 A MXPA04003508 A MX PA04003508A MX PA04003508 A MXPA04003508 A MX PA04003508A
Authority
MX
Mexico
Prior art keywords
binding
antibodies
repeat
human anti
proteoglycan
Prior art date
Application number
MXPA04003508A
Other languages
English (en)
Spanish (es)
Inventor
Rinkenberger Julie
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MXPA04003508A publication Critical patent/MXPA04003508A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA04003508A 2001-10-18 2002-10-18 Anticuerpos humanos que se unen a mn. MXPA04003508A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02
PCT/US2002/033470 WO2003033674A2 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Publications (1)

Publication Number Publication Date
MXPA04003508A true MXPA04003508A (es) 2004-07-22

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003508A MXPA04003508A (es) 2001-10-18 2002-10-18 Anticuerpos humanos que se unen a mn.

Country Status (18)

Country Link
US (2) US7462696B2 (enExample)
EP (1) EP1438339A4 (enExample)
JP (2) JP2005528884A (enExample)
KR (1) KR20050037478A (enExample)
CN (1) CN1606569A (enExample)
AR (1) AR036833A1 (enExample)
BR (1) BR0213968A (enExample)
CA (1) CA2463943A1 (enExample)
CO (1) CO5370684A1 (enExample)
DO (1) DOP2002000494A (enExample)
HU (1) HUP0600335A2 (enExample)
IL (1) IL161411A0 (enExample)
MX (1) MXPA04003508A (enExample)
PE (1) PE20030473A1 (enExample)
PL (1) PL374304A1 (enExample)
RU (1) RU2317998C2 (enExample)
UY (1) UY27499A1 (enExample)
WO (1) WO2003033674A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
EP4001920A1 (en) * 2014-04-03 2022-05-25 AllerGenis, LLC Peptides and methods for detecting food allergy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
AU758957C (en) * 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
PE20030473A1 (es) 2003-06-26
CO5370684A1 (es) 2004-02-27
UY27499A1 (es) 2003-05-30
RU2317998C2 (ru) 2008-02-27
WO2003033674A3 (en) 2003-08-21
CA2463943A1 (en) 2003-04-24
US20100240100A1 (en) 2010-09-23
DOP2002000494A (es) 2004-05-31
AR036833A1 (es) 2004-10-06
PL374304A1 (en) 2005-10-03
IL161411A0 (en) 2004-09-27
JP2010260845A (ja) 2010-11-18
KR20050037478A (ko) 2005-04-22
US7462696B2 (en) 2008-12-09
WO2003033674A2 (en) 2003-04-24
CN1606569A (zh) 2005-04-13
BR0213968A (pt) 2005-05-10
EP1438339A2 (en) 2004-07-21
HUP0600335A2 (en) 2006-08-28
US20030077277A1 (en) 2003-04-24
JP2005528884A (ja) 2005-09-29
EP1438339A4 (en) 2008-08-27
RU2004115112A (ru) 2005-04-27

Similar Documents

Publication Publication Date Title
WO2003033674A3 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
WO2023034922A3 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
CN102633881B (zh) 针对her-3的抗体及其用途
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
WO2004001381A8 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
AR113225A2 (es) Anticuerpo monoclonal aislado que se une específicamente a cxcr4 humano expresado sobre la superficie de una célula y que es capaz de inducir apoptosis de célula tumorales cxcr4⁺ in vivo
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
WO2004074320A3 (en) Therapeutic targets in cancer
WO2005031001A3 (en) Novel therapeutic targets in cancer
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
WO2006099141A3 (en) Anti-mesothelin antibodies
JP2009529497A5 (enExample)
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
WO2005012493A3 (en) Anti-cd19 antibodies
WO2004032857A3 (en) Antibody therapy
EP2559705A3 (en) Anti-activin a antibodies and uses thereof
MY144620A (en) Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumors
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
MXPA03009924A (es) Anticuerpo recombinante especifico de tumor y uso del mismo.
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
AU9021898A (en) Prostate tumor polynucleotide and antigen compositions
Rochaix et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
ATE412756T1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal